All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Can JAK2V617F VAF variations help predict clinical and survival outcomes?

Jan 2, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in JAK2V617F VAF variations.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Can JAK2V617F variant allele frequency (VAF) variations help predict clinical and survival outcomes?

Can JAK2V617F VAF variations help predict clinical and survival outcomes?

Harrison opens by discussing the latest data presented at the 64th ASH Annual Meeting and Exposition from a range of studies on the relationship between JAK2V617F VAF variations and progression-free survival, event-free survival, overall survival, and molecular response. Harrison concludes by outlining the promising developments for molecular monitoring in the field of myeloproliferative neoplasms.